In the US, Lurasidone (lurasidone systemic) is a member of the drug class atypical antipsychotics and is used to treat Bipolar Disorder, Borderline Personality Disorder, Schizoaffective Disorder and Schizophrenia.
ATC (Anatomical Therapeutic Chemical Classification)
CAS registry number (Chemical Abstracts Service)
- Lurasidonum (Latin)
- Lurasidon (German)
- Lurasidone (French)
- Lurasidona (Spanish)
- Lurasidone Hydrochloride (OS: USAN, JAN)
- SM-13496 (IS)
- UNII-O0P4I5851I (IS)
Takeda, Poland; Takeda Pharma, Slovenia; Medius, Switzerland; Sunovion, United States; Sunovion Pharmaceuticals, Canada; Sunovion Pharmaceuticals Europe, United Kingdom; Takeda, Germany; Takeda, Finland
|JAN||Japanese Accepted Name|
|Rec.INN||Recommended International Nonproprietary Name (World Health Organization)|
|USAN||United States Adopted Name|
|WHO||World Health Organization|
Further information on drug naming conventions: International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.